Riskpilot← Back to searchSign inGet full accessCross Pharma AB
ABIn liquidationOrg 5566604541Wholesale of pharmaceutical and medical goods · NACE 4646Est. 20040 employees
Revenue 2021
SEK 0
EBITDA margin
—
+116% vs 2020
Equity ratio
99.7%
Financial strength
Net profit 2021
SEK 150K
-98% vs 2020
| Revenue | SEK 0 | — |
| EBITDA | SEK 104K | +116% |
| Net profit | SEK 150K | -98% |
| Total assets | SEK 10,2M | -7% |
| Equity | SEK 10,2M | +1% |
| Employees | 0 | — |
Legal name
Cross Pharma AB
Org number
5566604541
Legal form
Aktiebolag
NACE code
4646 · Wholesale of pharmaceutical and medical goods
Founded
17 april 2004
Share capital
SEK 100 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2021-12-31
Financial year
January – December
Signatory rights
Firman tecknas ensam av likvidatorn
Company purpose
Bolaget skall bedriva import och försäljning av läkemedel samt därmed förenlig verksamhet.
Address
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Revenue | 110 636 | 33 544 | 69 | 2 | 0 |
| Staff expenses | — | — | — | — | — |
| EBITDA | 1 076 | −7 884 | −1 017 | −667 | 104 |
| Depreciation & amort. | −319 | −0 | −0 | −0 | −0 |
| EBIT | 757 | −7 884 | −1 017 | −667 | 104 |
| Net financials | −1 244 | −8 184 | −3 843 | −2 565 | −459 |
| Profit before tax | −442 | −16 068 | −4 860 | 6 074 | 150 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −442 | −16 068 | −4 860 | 6 074 | 150 |
| Item | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|
| Total assets | 51 660 | 11 244 | 4 586 | 10 986 | 10 228 |
| Equity | 14 165 | 8 831 | 3 971 | 10 046 | 10 196 |
| Long-term debt | 0 | 1 260 | 215 | 0 | 0 |
| Short-term debt | 37 495 | 1 153 | 400 | 940 | 32 |
| Total debt | 37 495 | 2 413 | 615 | 940 | 32 |
EBITDA margin
10400000.0%
This company
15.8%
Market median
+65822685% vs market
20172021
Equity ratio
99.7%
This company
38.2%
Market median
+161% vs market
20172021
Return on equity
1.5%
This company
18.4%
Market median
-92% vs market
20172021
Net profit margin
15000000.0%
This company
8.1%
Market median
+185185085% vs market
20172021
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20172021
Debt / equity
0.00×
This company
0.62×
Market median
+100% vs market
20172021
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Bolagsverket / SCB · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Bolagsverket / SCB · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Bolagsverket / SCB · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Bolagsverket / SCB · Period 2017-05-01 – 2017-12-31
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
SK Liquidator | Liquidator | 2022 |
SM | Audit | 2022 |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 100% | 100% | 0001 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
MedCap AB (publ)Unimedic Pharma Holding ABUnimedic Aktiebolag
Cross Pharma AB (this company)Prodlekpol Sp z o oBoard members of Cross Pharma AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Snickar Karl Johan Tobieson | Liquidator | 0 companies |
| Sven Michael Christensson | Audit | 0 companies |